Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482403 · ClinicalTrials.gov registry record · Phase 2
A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01482403 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 58 participants.
The verdict
NCT01482403, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This randomized, double-blind, multi-center, placebo-controlled, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) in combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C infection. The anticipated time on study treatment is up to 48 weeks.
Interventions
- DRUG Copegus
- DRUG Pegasys
- DRUG boceprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482403
The ClinicalTrials.gov registry entry for NCT01482403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Copegus is the first listed.
NCT01482403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482403 about?
NCT01482403 is a clinical study titled "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C". This randomized, double-blind, multi-center, placebo-controlled, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) in combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C infection. The anticipated time on s...
What is the current status of trial NCT01482403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2011-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01482403?
The interventions under investigation include: Copegus (DRUG), Pegasys (DRUG), boceprevir (DRUG).
Who is sponsoring clinical trial NCT01482403?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.